**Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic *EGFR* Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies**

Antonio Passaro, et al.

|  |  |
| --- | --- |
| **Category**  | **Patient subgroup** |
| All patients |  |
| N  | 1108 |
| Median DOR, months (95% CI) | 13.2 (12.2–14.4) |
| Median DDC, months (95% CI) | 14.1 (13.6–14.8) |
| *EGFR* mutation type† | Common† | Uncommon‡ |
| N | 909 | 198 |
| Median DOR, months (95% CI) | 13.6 (12.5–14.8) | 10.2 (8.4–12.9) |
| Median DDC, months (95% CI) | 14.7 (13.9–15.9) | 9.1 (8.1–11.4) |
| ECOG PS | 0/1 | 2 |
| N | 1058 | 49 |
| Median DOR, months (95% CI) | 13.2 (12.2–14.8) | 8.3 (5.0–13.0) |
| Median DDC, months (95% CI) | 14.3 (13.7–15.2) | 9.9 (7.4–13.9) |
| ECOG PS (patients with common mutations)† | 0/1 | 2 |
| N | 869 | 40 |
| Median DOR, months (95% CI) | 13.8 (12.5–14.9) | 12.4 (5.0–14.1) |
| Median DDC, months (95% CI) | 14.8 (14.1–16.3) | 9.9 (6.2–13.9) |
| Afatinib line of therapy  | First-line | Second-line | >Second-line |
| N | 770 | 261 | 77 |
| Median DOR, months (95% CI) | 13.4 (12.2–14.8) | 12.6 (11.1–16.6) | 12.5 (8.3–18.7) |
| Median DDC, months (95% CI) | 14.5 (13.7–15.9) | 13.7 (12.9–15.7) | 12.0 (8.3–14.5) |
| Brain metastases at screening§ | Yes | No |
| N | 213 | 894 |
| Median DOR, months (95% CI) | 11.1 (8.3–12.3) | 14.1 (13.0–15.4) |
| Median DDC, months (95% CI) | 11.7 (10.2–13.8) | 14.7 (13.9–16.1) |
| Age, years | <75 years | ≥75 years |
| N | 989 | 119 |
| Median DOR, months (95% CI) | 13.0 (12.0–14.1) | 16.5 (10.3–21.2) |
| Median DDC, months (95% CI) | 14.1 (13.6–15.0) | 14.1 (12.6–21.4) |
| Age, years | <65 years | ≥65 years |
| N | 685 | 423 |
| Median DOR, months (95% CI) | 12.5 (11.3–13.8) | 14.2 (12.4–17.3) |
| Median DDC, months (95% CI) | 13.7 (12.8–14.5) | 15.0 (13.8–17.3) |

**SUPPLEMENTARY TABLE 1 |** Post-hoc analysis ofduration of objective response and duration of disease control for specified subgroups.

*CI, confidence interval; DDC, duration of disease control; DOR, duration of objective response; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.* ***†****Patients with EGFR mutation categories of Del19 only or L858R only. ‡Patients with EGFR mutation categories other than Exon19 only and L858R only. §Asymptomatic.*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **T790M (n = 8)** | **Exon 20 ins (n = 36)** | **Major (n = 62)** | **Compound (n = 12)** | **Compound with Major (n = 8)** | **Other (n = 5)** |
| Patients with objective response, n (%) | 1 (12.5) | 9 (25.0) | 28 (45.2) | 6 (50.0) | 4 (50.0) | 2 (40.0) |
| Median DOR, months (95% CI) | 1.1 (NE–NE) | 9.1 (5.6–21.2) | 11.1 (7.1–17.2) | 17.9 (10.2–35.3) | 17.9 (10.2–35.3) | 4.7 (2.7–6.8) |

**SUPPLEMENTARY TABLE 2 |** Objective response rate and duration of objective response in patients with uncommon *EGFR* mutations.

*CI, confidence interval; DOR, duration of objective response; NE, not evaluable.*

**SUPPLEMENTARY FIGURE 1 |** Patient disposition. AEs, adverse events.

**SUPPLEMENTARY FIGURE 2** | TTSP in **(A)** all patients, **(B)** patients with tumors harboring common versus uncommon mutations, **(C)** patients with ECOG PS 0/1 versus 2, **(D)** patients with common mutations and ECOG PS 0/1 versus 2, **(E)** patients with vs without baseline brain metastases, **(F)** patients treated with afatinib in first, second and later lines of therapy, **(G)** patients aged <65 or ≥65 years, and **(H)** patients aged <75 or ≥75 years. Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TTSP, time to symptomatic progression.

****